Form 4: Teladoc CEO Divita Reports RSU Vesting and Tax-Related Stock Sale

Teladoc Health CEO Charles Divita III reported the vesting of 39,160 restricted stock units into common stock and a subsequent sale of 16,787 shares to cover tax obligations.

Summary

• Teladoc Health, Inc. CEO Charles Divita III reported transactions involving company common stock and restricted stock units (RSUs).
• On September 10, 2025, 39,160 restricted stock units converted into an equal number of common shares.
• Following this conversion, Mr. Divita beneficially owned 195,801 shares of common stock directly.
• On September 11, 2025, Mr. Divita sold 16,787 shares of common stock at a price of $7.5913 per share.
• This sale was conducted to cover tax withholding obligations arising from the vesting of his RSU awards.
• After the sale, Mr. Divita directly beneficially owned 179,014 shares of common stock.
• He still holds 274,123 restricted stock units.
• The RSUs were originally granted on June 10, 2024, totaling 469,924 units, with a vesting schedule of one-third on the first anniversary and the remainder in eight substantially equal quarterly installments.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation (RSU vesting and tax-related sale), which are neutral in sentiment and expected course of business.

Positives

• Vesting of 39,160 restricted stock units indicates continued long-term incentive alignment between the CEO and shareholder interests.
• The conversion of RSUs into common stock increases the CEO's direct equity ownership in the company, prior to the tax-related sale.

Negatives

• The sale of 16,787 shares, even for tax purposes, reduces the CEO's direct beneficial ownership of common stock.
• The sale price of $7.5913 per share could be seen as relatively low, depending on the company's historical stock performance and future outlook.

Risks

• No specific risks are mentioned in this Form 4 filing, which primarily reports insider transactions.

Future Outlook

The filing indicates future vesting events for the remaining 274,123 restricted stock units, which are scheduled to vest in eight substantially equal quarterly installments following the initial one-third vesting on June 10, 2025.

Industry Context

This Form 4 filing reports a routine insider transaction related to equity compensation. It does not provide information that directly impacts broader industry trends or competitive analysis within the telehealth sector. Such transactions are common across all industries for executives receiving equity-based compensation.

Comparison to Industry Standards

• The reported RSU vesting and subsequent tax-related sale are standard practices for executive compensation in publicly traded companies across various industries.
• The sale to cover tax obligations is a common and expected event when equity awards vest, aligning with typical compensation structures for CEOs in the technology and healthcare sectors.
• No specific comparable companies or projects are mentioned in this transactional filing.

Stakeholder Impact

• Shareholders: Minor, routine insider transaction. The sale of shares for tax purposes slightly reduces the CEO's direct ownership but is a common practice.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Next Steps

• Future quarterly vesting of the remaining 274,123 restricted stock units.

Key Dates

Keywords

Teladoc Health, TDOC, Charles Divita III, CEO, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding, Equity Compensation